Liquidia Technologies Inc Market Cap ($4.03 Billion)

$4.03 Billion USD  · Rank #3969

Market Cap & Net Worth: Liquidia Technologies Inc (LQDA)

Liquidia Technologies Inc market cap. Liquidia Technologies Inc (NASDAQ:LQDA) has a market capitalization of $4.03 Billion ($4.03 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3969 globally and #1411 in its home market, demonstrating a 13.53% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liquidia Technologies Inc's stock price $45.06 by its total outstanding shares 89508891 (89.51 Million).

Liquidia Technologies Inc Market Cap History (2018–2026)

Liquidia Technologies Inc market cap history from 2018 to 2026. Data shows growth from $1.94 Billion to $4.03 Billion (18.46% CAGR). Check Liquidia Technologies Inc stock price for real-time trading data and today's change.

Index Memberships

Liquidia Technologies Inc is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NASDAQ Health Care
IXHC
$2.62 Trillion 0.15% #105 of 976
NASDAQ Composite
IXIC
$40.09 Trillion 0.01% #463 of 3165

Weight: Liquidia Technologies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Liquidia Technologies Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Liquidia Technologies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see LQDA operating cash flow for how efficiently the company converts equity into cash flow.

Latest Price to Sales (P/S) Ratio

19.50x

Liquidia Technologies Inc's market cap is 19.50 times its annual revenue

Industry average: 0.56x Higher than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2018 $1.94 Billion $2.71 Million -$53.14 Million 716.21x N/A
2019 $382.65 Million $8.07 Million -$47.58 Million 47.40x N/A
2020 $264.05 Million $739.63K -$59.76 Million 357.01x N/A
2021 $435.91 Million $12.85 Million -$34.58 Million 33.91x N/A
2022 $570.17 Million $15.94 Million -$41.02 Million 35.78x N/A
2023 $1.08 Billion $17.49 Million -$78.50 Million 61.57x N/A
2024 $1.05 Billion $14.00 Million -$130.39 Million 75.21x N/A
2025 $3.09 Billion $158.32 Million -$68.92 Million 19.50x N/A

Competitor Companies of LQDA by Market Capitalization

Companies near Liquidia Technologies Inc in the global market cap rankings as of October 31, 2026. See net asset quality index of Liquidia Technologies Inc to understand what proportion of total assets are financed by equity.

Key companies related to Liquidia Technologies Inc by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#511 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#535 GALDERMA GROUP AG NYSE:GALDY $50.42 Billion $46.62
#593 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $45.23 Billion CN¥48.46
#619 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €18.30

Market Capitalization of Liquidia Technologies Inc (2018–2026)

Market capitalization of Liquidia Technologies Inc from 2018 to today. Between 2018 and today, Liquidia Technologies Inc's market cap moved from $1.94 Billion to $ 4.03 Billion, with a yearly change of 18.46%.

Year Market Cap Change (%)
2026 $4.03 Billion +30.65%
2025 $3.09 Billion +193.28%
2024 $1.05 Billion -2.24%
2023 $1.08 Billion +88.85%
2022 $570.17 Million +30.80%
2021 $435.91 Million +65.08%
2020 $264.05 Million -30.99%
2019 $382.65 Million -80.26%
2018 $1.94 Billion --

End of Day Market Cap According to Different Sources

On Oct 31st, 2026 the market cap of Liquidia Technologies Inc was reported to be:

Source Market Cap
Yahoo Finance $4.03 Billion USD
MoneyControl $4.03 Billion USD
MarketWatch $4.03 Billion USD
marketcap.company $4.03 Billion USD
Reuters $4.03 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Liquidia Technologies Inc

NASDAQ:LQDA USA Drug Manufacturers - Specialty & Generic
Market Cap
$4.03 Billion
Market Cap Rank
#3969 Global
#1411 in USA
Share Price
$45.06
Change (1 day)
+0.16%
52-Week Range
$25.22 - $91.03
All Time High
$91.03
About

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more